CAI:MIPH's Forward Dividend Yield % is ranked worse than 88.06% of 511
companies
in the Drug Manufacturers industry
Industry Median: 2.01
vs CAI:MIPH: 0.36
During the past 12 months, Minapharm Pharmaceuticals's average Dividends Per Share Growth Rate was 51.50% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was -5.10% per year.
During the past 5 years, the highest 3-Year average Dividends Per Share Growth Rate of Minapharm Pharmaceuticals was -5.10% per year. The lowest was -15.10% per year. And the median was -10.10% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Minapharm Pharmaceuticals Forward Dividend Yield % Related Terms
CAI:MIPH vs ZTS, UTHR, VTRS: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minapharm Pharmaceuticals Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Minapharm Pharmaceuticals's Forward Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Minapharm Pharmaceuticals Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
EGP 2.500000
2025-08-13
2025-08-14
0000-00-00
Cash Dividend
annually
EGP:EGP 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Dividend Yield % of 0.36% mean?
Minapharm Pharmaceuticals (CAI:MIPH) has a Forward Dividend Yield % of 0.36% as of Jul. 13, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Minapharm Pharmaceuticals and its competitors. According to the industry distribution chart, Minapharm Pharmaceuticals ranks #450 out of 511 companies in the Drug Manufacturers industry, placing it in the top 88.1%.
Is Minapharm Pharmaceuticals' Forward Dividend Yield % too high?
Minapharm Pharmaceuticals' current Forward Dividend Yield % is 0.36%. The Drug Manufacturers industry median Forward Dividend Yield % is 2.01. Minapharm Pharmaceuticals' value of 0.36% is 82.1% below this industry median. Based on the distribution chart, Minapharm Pharmaceuticals ranks #450 out of 511 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Minapharm Pharmaceuticals has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Minapharm Pharmaceuticals ranks #450 out of 511 companies for Forward Dividend Yield %. This places Minapharm Pharmaceuticals in the lower half of its industry. The industry median Forward Dividend Yield % is 2.01. Minapharm Pharmaceuticals' value of 0.36% is 82.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.01, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Minapharm Pharmaceuticals's current Forward Dividend Yield % of 0.36% is 82.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Minapharm Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minapharm Pharmaceuticals's current Forward Dividend Yield % is 0.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£362.13, compared to a current price of E£698.08 — trading 92.8% above its estimated fair value. The current Forward Dividend Yield % is 0.36% and 82.1% below the Drug Manufacturers industry median of 2.01. Minapharm Pharmaceuticals' overall GF Score™ is 41/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current Forward Dividend Yield % is 0.36% as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued.
The current stock price of E£698.08 is trading 92.8% above its estimated GF Value™ of E£362.13.
GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CAI:MIPH:
Forward Dividend Yield %: 0.36%
GF Value™: E£362.13 vs. price of E£698.08 (92.8% above fair value)
Industry Position: 82.1% below the Drug Manufacturers median (#450 of 511)
No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
41GF Score
Get the complete analysis for CAI:MIPH
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:MIPH has been successfully added to your 